◆ Investors offered identical deals at each end of the rating spectrum ◆ Sanofi appears to come flat to fair value ◆ Both get more demand for seven year tranches
Mike Turner,June 16, 2025
Gift this article
As a premium subscriber, you can gift this article for free
https://www.demo.com/demo-article/
Link copied to clipboard
You have reached the limit for gifting for this month
There was an error processing the request. Please try again later.